Posted by Michael Wonder on 10 Oct 2019
Elmiron bags draft NICE approval
10 October 2019 - NICE has published a draft final appraisal regarding Elmiron (pentosan polysulfate sodium) for bladder pain syndrome.
The organisation recommended that the drug is used in accordance with specified considerations, as the only licensed oral medication for BPS with glomerulations or Hunner’s lesions – also known as interstitial cystitis/BPS.
Elmiron is thought to work by restoring a damaged, thin, or “leaky” bladder surface which has a coating of mucus which protects the bladder wall from bacteria and irritating substances in urine. It is believed that the drug functions as a synthetic GAG layer, but its exact mechanism of action in IC/BPS is unclear.
